Elan's AD Drug Down, Not Out: J&J Pledges $1.5B in Venture
Johnson & Johnson plans to make a whopping $1.5 billion investment in Elan Corp. plc in exchange for a stake in Dublin-based Elan, in a deal that will transfer key Alzheimer's programs, including Phase III bapineuzumab, to the U.S. drugmaker. (BioWorld Today)
There's no Expiration on this Knowledge, but the Education Opportunity will Expire July 31!
Catch up on what you've missed for 40% off! This is your opportunity to get in the know and listen to noted speakers in the industry discuss current topics affecting your business today. BioWorld Today and Medical Device Daily offers this special rate through July 31, 2009. Click here and order now!
Arthritis Is Making a Killing in a Maturing Market
I well remember the day I ceded control of my spinal column. Years ago, I bent over at the waist with my daughter in one arm to pick up my house keys. I felt a disturbance in my lumbar force that felt like lava running down my spine. It was just my spine crying and giving me a preview of the abyss of suffering that I was to experience forevermore at the whim of my musculoskeletal system. As I fought blacking out, visions of my dad recurred with his admonition, "Bend with your knees — your waist is only good for holding up your pants!" It was too late. (BioWorld Perspectives)
UK Committing £150M to Grow Biotech Innovation, Start-ups
LONDON — The UK government is putting in £150 million (US$248 million) as a cornerstone investor in what it hopes will become a £1 billion fund for biotech and other high-tech start-ups over the next 10 years. (BioWorld International)
